Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives - ScienceDirect

Effect of the most common EGFR mutations in NSCLC (Non-small-cell lung

Frequency of driver mutations in Brazilian non‐small‐cell lung cancer

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

JCM, Free Full-Text

PDF] Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Cancers, Free Full-Text

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers